Skip to main content
. 2015 Sep 3;6(30):30287–30294. doi: 10.18632/oncotarget.4711

Figure 1A. Overall Survival.

Figure 1A

There was no significant difference in OS between patients with KRAS WT and KRAS MT (median OS 19 months vs. 15.6 months, p = 0.34).